-The Times of India So much has already been written on the food security Bill that there would seem to be no justification for another column on it. Yet, a recent look at some consumption data has convinced me otherwise. How the food security Bill impacts people's lives ultimately depends on the effect it will have on the consumption basket of the beneficiaries. If you believe in serious analysis over flag waving,...

-Outlook The Maoists want a military conflict as it brings more adivasis into their fold. The Indian state's best bet is in ensuring that it wins over the aam adivasis to its side.   May 25th's condemnable attack by the People's Liberation Guerrilla Army, which ended up killing and injuring over 50 people from Congress politicians to migrant adivasi labourers, cannot be understood without recognising the Maoist party's explicit political aims. These...

-The Business Standard Having quit the National Advisory Council (NAC), Aruna Roy of the Mazdoor Kisan Sangharsh Samiti (MKSS) will intensify the movement to get minimum wages countrywide under the Mahatma Gandhi National Rural Employment Guarantee Act and a Rs 1,000 a month pension for unorganised labourers. She will also press the government to make it mandatory to have a pre-legislation process for all bills that the government proposes to introduce...

-The Hindu     The killings of Mahendra Karma and his colleagues call not for retributive violence but for a deeper reflection on the discontent among the tribals of central India and their dispossession In the summer of 2006, I had a long conversation with Mahendra Karma, the Chhattisgarh Congress leader who was killed in a terror attack by the Naxalites last week. I was not alone - with me were five other members...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...